転移性固形腫瘍を有する被験者におけるSLV 154の第1相用量漸増研究
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
調査の概要
詳細な説明
A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-154. Once the initial RDR is established in the Phase 1a portion of this study, further development in the Phase 1b expansion portion of this study will be considered in patients with specific cancers. In the Phase 1b part of this study, enrollment of each tumor-specific cohort will be performed using a Simon 2-stage optimal design.
SLV-154 will be administered intravenously (IV) in repeated 3-week cycles. Treatment will continue until progressive disease or discontinuation.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Langdon L Miller, MD
- 電話番号:908-906-6471
- メール:lmiller@solvetx.com
研究連絡先のバックアップ
- 名前:Hong Ren, MD
- 電話番号:425-894-2558
- メール:hren@solvetx.com
研究場所
-
-
California
-
Newport Beach、California、アメリカ、92663
- 募集
- Hoag Memorial Hospital Presbyterian
-
コンタクト:
- Cindy Do, BSN, RN
- 電話番号:949-764-4624
- メール:cindy.do@hoag.org
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University
-
コンタクト:
- Sara Mitchum
- 電話番号:314-273-8602
- メール:saram@wustl.edu
-
-
New Jersey
-
East Brunswick、New Jersey、アメリカ、08816
- 募集
- Astera Cancer Care
-
コンタクト:
- Percy Yeung
- 電話番号:732-387-3378
- メール:percy.yeung@asterahealthcare.org
-
-
New York
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center
-
コンタクト:
- Roisin O'Cearbhaill, MD
- 電話番号:646-888-4227
- メール:ocearbhr@mskcc.org
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- 募集
- University Hospitals Cleveland Medical Center
-
コンタクト:
- Afshin Dowlati, MD
- 電話番号:212-844-6031
- メール:afshin.dowlati@UHhospitals.org
-
Columbus、Ohio、アメリカ、43210
- 募集
- The James Outpatient Care West Center
-
コンタクト:
- Adam Roan
- 電話番号:614-685-0587
- メール:Adam.Roan@osumc.edu
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19111
- 募集
- Fox Chase Cancer Center
-
コンタクト:
- Dajah White-Dumpson
- 電話番号:215-214-1600
- メール:Dajah.White-Dumpson@fccc.edu
-
コンタクト:
- Shannon Fabrie
- 電話番号:215-728-3620
- メール:shannon.fabrie@fccc.edu
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- MD Anderson Cancer Center
-
コンタクト:
- Rabia Khan
- 電話番号:713-563-4667
- メール:RKhan@mdanderson.org
-
Houston、Texas、アメリカ、77030
- 募集
- Oncology Consultants
-
コンタクト:
- Julio Peguero, MD
- 電話番号:713-600-0900
- メール:jPeguero@oncologyconsultants.com
-
San Antonio、Texas、アメリカ、78229
- 募集
- Mays Cancer Center; University of Texas Health San Antonio
-
主任研究者:
- Daruka Mahadevan
-
コンタクト:
- Daruka Mahadevan, MD
- 電話番号:210-450-1000
- メール:mahadevand@uthscsa.edu
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 募集
- University of Washington / Fred Hutchinson Cancer Center
-
コンタクト:
- Phase 1 Clinical Trials
- 電話番号:206-606-7551
- メール:phase1clinicaltrial@fredhutch.org
-
Tacoma、Washington、アメリカ、98405
- 募集
- Northwest Medical Specialties, PLLC
-
コンタクト:
- CarrieAnn Brown
- 電話番号:253-428-8700
- メール:cbrown@nwmsonline.com
-
コンタクト:
- Kiersten Peart
- 電話番号:253-428-8700
- メール:kpeart@nwmsonline.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Men or women (as appropriate for cancer type) of age ≥12 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
- Presence of metastatic or recurrent locally advanced cancer.
- Presence of radiographically measurable disease.
- Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
- Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
- Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
- Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
- Adequate hematological profile.
- Adequate coagulation profile.
- Adequate hepatic profile.
- Adequate renal function.
- Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
- For female subjects of childbearing potential, a negative serum pregnancy test.
- For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
- For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
- Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
- Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion Criteria:
- Unstable malignancy involving the central nervous system.
- Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
- Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
- Significant cardiovascular event or comorbidity.
- Significant screening ECG abnormalities.
- Pregnancy or breastfeeding.
- Major surgery within 3 weeks before the start of study therapy.
- Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
- Concurrent participation in another therapeutic or imaging clinical trial.
- Other conditions likely to interfere with a subject's ability to participate in the study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Dose Level 1
0.75 mg/kg |
SLV-154 |
|
実験的:Dose Level 2
1.5 mg/kg |
SLV-154 |
|
実験的:Dose Level 3
3.0 mg/kg |
SLV-154 |
|
実験的:Dose Level 4
4.0 mg/kg |
SLV-154 |
|
実験的:Dose Level 5
5.0 mg/kg |
SLV-154 |
|
実験的:Dose Level 6
6.5 mg/kg |
SLV-154 |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase 1a: MTD and/or RDR
時間枠:Through the duration of treatment, up to approximately 18 months
|
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154. |
Through the duration of treatment, up to approximately 18 months
|
|
Phase 1b: Objective response rate (ORR)
時間枠:Through the duration of treatment, up to approximately 18 months
|
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR). |
Through the duration of treatment, up to approximately 18 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
SLV-154 administration
時間枠:Through the duration of treatment, up to approximately 18 months
|
SLV-154 drug administration as assessed by prescribing records |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Safety
時間枠:Through the duration of treatment, up to approximately 18 months
|
Collection of type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign/oxygen saturation abnormalities; adverse electrocardiogram (ECG) findings; DLTs; serious adverse events (SAEs); adverse events of special interest (AESIs); or adverse events (AEs) leading to interruption, modification, or discontinuation of study drug administration. |
Through the duration of treatment, up to approximately 18 months
|
|
Evaluation of use of concomitant medications
時間枠:Through the duration of treatment, up to approximately 18 months
|
Type, frequency, and timing of use of supportive care and other concomitant medications |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Pharmacokinetics
時間枠:Varying timepoints through the duration of treatment, up to approximately 18 months
|
Evaluation of the pharmacokinetic profile of SLV-154 |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Immunogenicity
時間枠:Varying timepoints through the duration of treatment, up to approximately 18 months
|
Measurement of changes in titers of circulating SLV 154-reactive antibodies (as assessed using immunoassay methods) |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Time to Response (TTR)
時間枠:Up to approximately 36 months
|
TTR: interval from the start of study drug administration to the first documentation of objective tumor regression |
Up to approximately 36 months
|
|
Duration of Response (DOR)
時間枠:Up to approximately 36 months
|
DOR: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
4-month progression-free survival (PFS4)
時間枠:Up to approximately 36 months
|
PFS4: proportion of subjects who are alive and have not experienced disease progression at 4 months after the start of study drug administration |
Up to approximately 36 months
|
|
6-month progression-free survival (PFS6)
時間枠:Up to approximately 36 months
|
PFS6: proportion of subjects who are alive and have not experienced disease progression at 6 months after the start of study drug administration |
Up to approximately 36 months
|
|
Time to treatment failure (TTF)
時間枠:Up to approximately 36 months
|
TTF: interval from the start of study drug administration to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause |
Up to approximately 36 months
|
|
Overall survival (OS)
時間枠:Up to approximately 36 months
|
OS: interval from the start of study drug administration to death from any cause |
Up to approximately 36 months
|
|
Disease benefit ratio (DBR)
時間枠:Up to approximately 36 months
|
DBR: proportion of subjects who experience CR, PR, or stable disease with tumor reduction (SDTR) |
Up to approximately 36 months
|
|
Progression free survival (PFS)
時間枠:Up to approximately 36 months
|
PFS: interval from the start of study drug administration to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
Duration of disease benefit (DDB)
時間枠:Up to approximately 36 months
|
DDB: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause in subjects with disease benefit |
Up to approximately 36 months
|
|
Percent change in tumor dimensions
時間枠:Up to approximately 36 months
|
percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions |
Up to approximately 36 months
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SLV-154-01Tx
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Results will be presented in clinical study reports and publications. Individual participant data will not be shared with other researchers.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。